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Abstract 
 
The research aim was to develop an emulgel formulation of the defatted ethyl acetate extract of Mychorriza arbuscule fungi 
induced ginger rhizomes (MIG) as a topical anti-inflammation dosage form by using optimization technique. A complete 
randomized design with two factors and two levels was used. The concentration of gelling base (hydroxyl propyl methyl 
cellulose, HPMC, at levels 0.75 and 2%) and the concentration of the extract (at levels 8 and 16%) were used as 
independent variables while the viscosity and the percentage of edema inhibition of the dosage form were taken as the 
response variables. Four (22) formulations were prepared: F1, Fa, Fb, and Fab. As a marker, 6-gingerol was used which 
concentration was determined by TLC-densitometry with silica gel GF254 as a stationary phase and n-hexane : ethyl acetate 
(13:7) as a  mobile phase. Data were analyzed using multi regression analysis, the optimum formula was obtained from the 
intercept of the superimposed contour plot. The TLC densitometry system showed that the marker and the extract had a 
retention factor of 0.3. The 6-gingerol concentration of F1 was 0.31%; Fa 0.38%; Fb 0.82%; Fab 0.81%; and the defatted 
extract 3.67%. The viscosity of each formula was 10 (F1), 200 (Fa). 5 (Fb) and 150 (Fab) dPa.s, respectively. The 
percentage of edema inhibition of the dosage form was 31.6% (F1), 31.3% (Fa), 45.5% (Fb) and 43.7% (Fab), respectively. 
The optimum formula of the emulgel is at HPMC concentration of 2% and the extract 12% which has a viscosity of 127.129 
dPa.s and edema inhibition 37.8%. 
Keywords: ginger extract, Mychorriza arbuscule fungi, optimization technique, emulgel, oedema inhibition 
 
 
1. Introduction 
Ginger has been used traditionally in Indonesia to treat swollen skin, nausea, vomiting and as a stimulant [1].  
The literature review shows that ginger extract has several pharmacological activities such as antiemetic, 
antimicrobial, anti-inflammation, analgesic, antioxidant, anticarcinogenic, and immunomodulatory [2-5]. The 
major compounds in the extract are 6-gingerol, 6-shogaol, paradol, methyl gingerol, gingerdiol, 
dehidrogingerdion, and gingerdion [2]. Gingerol and shogaol are known to exhibit anti-inflammatory activity 
by suppression the biosynthesis of inflammatory mediators [5, 6]. A previous study shows that MIG has higher 
shogaol and gingerol contents; the major compound of its defatted ethyl acetate extract is 6-gingerol [7, 8]. 
The bioactive components of ginger are very potential to be developed as an anti-inflammatory agent [5].  
A pharmacokinetic study shows low bioavailability of  6-gingerol (1.79%) and 6-shogaol (0.32%) in human 
after the ingestion of ginger extract [9]. Poor bioavailability of phenolic compounds from plant extract is 
associated with low concentration of the free phenolic forms in the blood due to either low absorption or 
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extensive metabolism in the intestinal epithelium and the liver [9, 10]. A transdermal dosage form of ginger 
extract may overcome this problem by providing sufficient quantities of the free gingerol and shogaol in the 
inflamed area.  The objective of this study is to develop an emulgel formulation of the defatted ethyl acetate 
extract of MIG by using optimization technique. As a control, an emulgel containing diclofenac sodium 
(Voltaren emulgel Novartis)  marketed in Indonesia is used. 
 
 
 
2.  Materials and Methods 
 
2.1 Materials 
Fresh MIG was supplied by PT Andalas Agrotama Padang (Indonesia); 6-gingerol was purchased from Sigma 
Aldrich®; n-hexane, ethyl acetate, sulphuric acid, and acetic acid were purchased from Merck®; HPMC K100M 
was from Wuhan Senwayer Century Chemical® (China); methanol, p-anisaldehyde, sodium hydroxide, 
potassium dihydrogen phosphate, propylene glycol, liquid paraffin, tween 80, span 80, methyl paraben, propyl 
paraben, and carrageenan were purchased from Bratachem® (Indonesia). All reagents and solvents were of 
pharmaceutical grade. 
 
 
2.2 Experimental animals 
Male albino rats (Rattus norvegicus) weighing 140-160 g were used as experimental animals. The animals 
were kept under observation before the experiment for acclimatization. The chosen animals were housed in 
plastic good aerated cages at the normal atmospheric temperature (24 ± 2°C) and normal 12 hours light/dark 
cycle. They were given access to water and standard diet of known composition. All animal procedures were 
undertaken with the approval of Institutional Animal Ethics Committee of the Faculty of Medicine, Andalas 
University. 
 
2.3 Methods 
 
2.3.1 Preparation of the defatted ethyl acetate extract of MIG 
The MIG was washed, dried, weighed and finely cut. The rhizomes were defatted with n-hexane and then 
extracted with ethyl acetate for 5 days at room temperature; the extraction was done in triplicates. The 
collected ethyl acetate extract was concentrated and dried in vacuo with a rotary evaporator (Buchi®) [8]. 
 
2.3.2 Experimental design 
Four emulgel formulations were prepared according to a 22 factorial design employing the factors and levels 
described in Tables 1, while the formula composition is shown in Table 2. 
 
 
Table 1. Factors and Levels for the 22 Factorial Design 
 
 
 
 
 
 
 
 
 
 
No Factor 
Level 
Low High 
1 HPMC K100M 0.75% 2.5 % 
2 The defatted ethyl acetate extract of MIG 8% 16% 
 
Harrizul Rivai et al, Int. Journal of Pharmaceutical Sciences and Medicine (IJPSM), 
Vol. 3 Issue. 3, March- 2018, pg. 1-8                         
 
© 2018, IJPSM All Rights Reserved, www.ijpsm.com                                                                         3 
Table 2. Composition of the defatted ethyl acetate extract of MIG Emulgel Formulations 
 
Formula F1 (%) Fa (%) Fb (%) Fab (%) 
HPMC K100M  0.75 2.5 0.75 2.5 
The defatted ethyl acetate extract of MIG  8 8 16 16 
Propylene glycol 10 10 10 10 
Liquid paraffin  5 5 5 5 
Tween 80 2 2 2 2 
Span 80 1 1 1 1 
Methylparaben 0.1 
0.1 
0.1 
0.1 
Propylparaben 0.1 
0.1 
0.1 
0.1 
Purified water to 100 100 100 100 
 
2.3.3  Preparation of the defatted ethyl acetate extract of MIG emulgel formulations 
The gelling base was prepared by dispersing HPMC K100M in heated purified water (80oC) then left cooled. 
The oil phase of the emulsion was prepared by dissolving span 80 in liquid paraffin while the aqueous phase by 
dissolving Tween 80 in purified water; methyl and propyl parabens were dissolved in propylene glycol which 
then mixed with the aqueous phase. Both oil and aqueous phases were separately heated to 70oC. The oily 
phase was added to the aqueous phase with gentle stirring to room temperature to obtain an emulsion. The 
emulsion was then mixed with the gelling base with gentle stirring to obtain an emulgel. The emulgel base was 
added to the MIG extract and stirred vigorously to ensure homogeneity. 
 
2.3.4  Examinations of the emulgels 
Formed emulgels were examined for physical characteristics, including colour, homogeneity, consistency, and 
phase separation. The pH values of 1% aqueous solutions of the emulgels were measured by a pH meter 
(Voltcraft®, Germany). The viscosity was determined at 25oC by using a cone and plate viscometer (Rion VT-
04F). Physical stability was observed during the storage at 25oC for 3 months. 
 
2.3.5  Quantitative analysis of 6-gingerol in emulgels 
The concentration of 6-gingerol in the extract and emulgel formulations was determined by TLC-densitometry 
method (Camag®) by using TLC plates 60 F254 as the stationary phase and n-hexane : ethyl acetate (13:7) as the 
mobile phase. The spot was sprayed with p-anisaldehyde, heated for 10 minutes and scanned with TLC scanner 
at wavelength 525 nm (Camag®). The methods were validated over the concentration of 62.5, 125, 250 and 
500µg/mL. 
 
2.3.6  The assay of anti-inflammatory activity 
The anti-inflammatory effect was examined by using the method of carrageenan-induced paw oedema in rats 
as described by Winter et al, 1962 [11]. The rats were divided into 6 groups, each consisted of 3 rats. Group I, 
II, III, and IV were the test groups given emulgel F1, Fa, Fb, and Fab, respectively. Group V was a control 
group received only the vehicle (gel base) and group VI was a reference group, received Voltaren® emulgel. 
Inflammation was induced by injecting 0.2 mL of 0.5% carrageenan suspension to the plantar surface of the 
right hind paw of each rat. The test groups of rats were treated by applying ± 0.2 g of the emulgels topically to 
the right hind foot of the rats after carrageenan injection. The volume of the inflamed paw was determined 
using a mercury plethysmograph (U. Basile, Italy) right after carrageenan injection (initial volume) and 6 hours 
after application of the emulgels (volume at time t). The percentage of oedema and that of oedema inhibition in 
treated rats versus control were calculated using Equations 1 and 2. 
% edema  =   x 100%  (Equation 1) 
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% edema inhibition  =   x 100% (Equation 2) 
 
Where Vt = the paw size at time t, Vo = the initial paw volume, a = the average paw volume of control group 
and b = the average paw volume of treated groups. 
 
2.3.7  Satistical analysis 
The effect of formulations expressed as (the average oedema + standard of deviation) were analysed by one-
way ANOVA (α = 0.05) to determine the significant differences between means followed by Duncan Multiple 
Range Test at 5% significance level.  The viscosity of emulgels and oedema inhibition were analysed using 
multi regression analysis by Design Expert and an optimum formula was selected from the superimposed 
contour plot of the viscosity and oedema inhibition responses. 
 
3. Resuts and Discussion 
A previous study reports that the defatted plant extract yields a higher total phenolic content [12]. In this study, 
a pre-extraction procedure with hexane was conducted to remove fatty oil, oleoresins, volatile oils and other 
lipophilic contents in MIG which might cause irritation for topical application and to obtain a higher gingerol 
and shogaol contents in the extract [5]. The higher phenolic content of the defatted extract might be due to an 
increase in the polarity after the removal of fatty substances [12]. 
The MIG extract concentration and the viscosity of dosage forms are two main factors influencing the anti-
inflammatory activity of the emulgel formulation.  Their levels were determined previously by measuring 
oedema inhibition of the extract at concentrations range of 2 – 16 % and determining the viscosity of the 
emulgel base at HPMC concentration of 0.75 – 2.5%. The low and high levels of the extract were 8 and 16% 
which obtained oedema inhibition of 32.90 and 49.65% respectively, the latter was not significantly different 
than that of the reference (p>0.05). The HPMC levels of 0.75 (low) and 2.5% (high) gave a consistency ranged 
from 20 – 250 dPa.s which were in the range of the viscosity of gel dosage forms [13]. 
The emulgels obtained were pale brown to brown opaque semi-solids with a specific ginger odour. The 
physicochemical characteristics of the emulgels are summarized in Table 3. There was a slight difference in the 
colour depending on the concentration of MIG extract in the emulgels. The pH value of the emulgel base was 
6.5, and that of the MIG formulations were 3.8 (F1), 2.6 (Fa), 3.7 (Fb) and 2.6 (Fab), respectively. These 
values were much lower than the skin pH which may increase the risk of irritation upon application to the skin. 
Skin patch test on human volunteers showed that F1 and Fa (8% MIG extract) did not cause irritation but Fb 
and Fab (16% MIG extract) did. Therefore, the formula containing the highest level of extract might not be an 
optimum formulation.  A gel base containing buffer component might be required to maintain the emulgels pH 
in the range suitable for a topical use. 
 
Table 3: Physicochemical properties of the ethyl acetate extract of MIG emulgels 
 
Parameters Formulations 
F1 Fa Fb Fab Emulgel 
base 
pH value 3.8 2.6 3.7 2.6 6.5 
6-gingerol content (%) 0.31 0.38 0.82 0.81 - 
Physical stability (25oC, 3 mos.) Stable Stable Stable Stable Stable 
Viscosity (dPaS) 10 200 5 150 20-250 
 
Data analysis of viscosity response (Y1) to the concentration of HPMC  (X1) and the MIG extract (X2) by using 
factorial design 22 obtains the following equation (equation 3) [14]:    
Y1 = 91.25 + 83.75 X1 – 13.75 X2 – 11.25 X1X2.    (Equation 3) 
This indicates that HPMC has a positive influence on the viscosity by +83.75. The MIG extract as an active 
ingredient had a negative effect on the viscosity by -13.75. An interaction between the two factors shows a 
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negative influence on the viscosity by -11.25. The contour plot showing the viscosity response of the gelling 
agent and the MIG extract levels is given in Figure 1. 
 
 
Figure 1: Contour plot for the viscosity response of the MIG extract emulgels as a function of the active 
ingredient and gelling base levels 
 
Quantitative analysis of 6-gingerol was carried out at the maximum wavelength of 525 nm and results in a spot 
with the retention factor of 0.3. Validation of the method shows a linear regression between concentration of 6-
gingerol versus absorbance (y = 1509.65 + 23.124 x; r = 0.995). The 6-gingerol content of the MIG extract is 
3.67% and that of the emulgels are in Table 3. 
The effect of the prepared emulgels on the reduction of rat’s paw oedema is presented in Table 4. The equation 
for the inflammatory inhibition response (Y2) based on factorial design 2
2 [14] is as follow: 
Y2 = 38.025 – 0.525 X1 + 6.5 X2 – 0.375 X1X2    (equation 4) 
Equation 4 shows a negative influence of HPMC on the inflammatory inhibition for -0.525 which means that 
an increase in the gelling base concentration reduces the anti-inflammatory effect of the emulgels. This might 
be due to a decrease in drug liberation as the viscosity increased [15]. On the other hand, the active ingredient 
has a positive effect on the anti-inflammatory activity of the emulgels by +6.5. An interaction between the 
HPMC effect and the anti-inflammatory effect is negative (-0.375).  Figure 2 shows the relationship between 
the HPMC level and the concentration of the MIG extract on the anti-inflammatory activity of the emulgels. 
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Table 4: Effect of MIG emulgels on carrageenan-induced paw oedema in rats 
 
Groups Treatment n Average edema + SD (%) Edema inhibition (%) 
Control Control 3 103.33 + 5.77d 0.0 
Test F1 3 70.67 + 3.52c 31.6 
Fa 3 70.90 + 1.56c 31.3 
Fb 3 56.33 + 3.18a 45.5 
Fab 3 58.17 + 3.18ab  43.7 
Reference Voltaren® 3 53.00 + 2.60a 48.7 
 
The effect of the prepared emulgels on the reduction of rat’s paw oedema is presented in Table 4. Analysis of 
the average oedema using one-way ANOVA shows a significant difference between formula. Furthermore, 
analysis by Duncan Multiple Range test suggests that the average oedema of Fb group was not significantly 
different than that of the reference group. The average oedema of the Fab group shows no significant 
difference than that of Fb, but it is different significantly than that of the reference group. These results indicate 
that emulgel formulations of the defatted ethyl acetate extract of MIG decrease inflammatory significantly 
(P<0.05). Fb shows a good percentage of oedema inhibition, but it might not be the best formulation. The 
edema inhibition of emulgels Fb and Fab (containing + 32 mg of 6-gingerol) is comparable with that of the 
ethanol extract of ginger at dose 50 mg/kg BW intraperitoneally which is 43% after 1-hour administration [11]. 
 
 
Figure 2: Contour plot for the anti-inflammatory inhibition of the MIG extract emulgels as a function of the 
active ingredient and gelling base levels 
 
An optimum formulation of the MIG extract emulgel is predicted from the superimposed contour plot of the 
viscosity and inflammatory inhibition responses. Figure 3 indicates the optimum HPMC level of 2% and the 
MIG extract concentration of 12% results in an emulgel with a viscosity of 127.129 dPaS and an inflammatory 
 
Harrizul Rivai et al, Int. Journal of Pharmaceutical Sciences and Medicine (IJPSM), 
Vol. 3 Issue. 3, March- 2018, pg. 1-8                         
 
© 2018, IJPSM All Rights Reserved, www.ijpsm.com                                                                         7 
inhibition of 37.8%. A preparation of the optimum formula and determination of the amount of 6-gingerol 
released are yet to be studied. 
 
Figure 3: A superimposed contour plot of the optimum emulgel formulation of the MIG extract 
 
4. Conclusion  
The optimum emulgel formulation of the MIG fraction consists of the HPMC level 2% and the MIG fraction 
level 12% which results in a viscosity of 127.129 dPaS and the inflammatory inhibition of 37.8%. 
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